EyePoint, Inc. Common Stock
EYPTEyePoint Pharmaceuticals, Inc. (EYPT) is a pharmaceutical company focused on developing and commercializing innovative therapies for eye diseases. The company specializes in treatments for retinal diseases, uveitis, and other ocular conditions, leveraging its expertise in drug delivery and molecular innovation to address unmet medical needs in ophthalmology.
Company News
EyePoint, Inc. granted non-statutory stock options to three new employees for up to 13,900 shares at an exercise price of $15.84 per share on January 15, 2026. The options vest over four years with a ten-year term. The company continues advancing its lead product DURAVYU in Phase 3 trials for wet AMD and DME, with data expected beginning mid-2026.
EyePoint announced progress on its lead product DURAVYU (vorolanib intravitreal insert) with Phase 3 wet AMD trials on track for data readout beginning mid-2026 and Phase 3 DME program first patient dosing expected in Q1 2026. The company completed enrollment of over 900 patients across wet AMD trials in 7 months and has approximately $300 millio...
EyePoint received a positive recommendation from its Data Safety Monitoring Committee for ongoing Phase 3 trials of DURAVYU, a potential treatment for wet age-related macular degeneration. The trials remain on track, with topline data expected in mid-2026.
EyePoint Pharmaceuticals reported Q3 2025 financial results, highlighting progress on DURAVYU clinical trials for wet AMD and diabetic macular edema, completed an oversubscribed $172.5 million equity financing, and positioned for key data readouts in mid-2026.
EyePoint Pharmaceuticals plans to raise approximately $150 million through a public offering of 11 million common stock shares and pre-funded warrants, with proceeds intended to advance clinical development of DURAVYU for retinal diseases.
